<SEC-DOCUMENT>0001104659-19-061688.txt : 20191108
<SEC-HEADER>0001104659-19-061688.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20191108161312
ACCESSION NUMBER:		0001104659-19-061688
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191108
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191108
DATE AS OF CHANGE:		20191108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		191204199

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm1922389d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
November 8, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 14pt">BIOANALYTICAL SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 26%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Registrant's telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act(17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act(17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act(17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 28%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Ticker symbol(s)</FONT></TD>
    <TD STYLE="width: 35%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">BASi</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><B><BR STYLE="clear: both">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2019,
Bioanalytical Systems, Inc. (the &ldquo;<U>Company</U>&rdquo;), and Bronco Research Services LLC, a wholly owned subsidiary of
the Company (the &ldquo;<U>Purchaser</U>&rdquo;), entered into an Asset Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;)
with Pre-Clinical Research Services, Inc., a Colorado corporation (the &ldquo;<U>Seller</U>&rdquo;), and its shareholder. Pursuant
to the Purchase Agreement, and subject to the terms and conditions thereof, the Company will indirectly acquire (the &ldquo;<U>Acquisition</U>&rdquo;)
substantially all of the assets of Seller used or useful by Seller in connection with Seller's provision of good laboratory practice
(&quot;<U>GLP</U>&quot;) and non-GLP preclinical testing for the pharmaceutical and medical device industries. The consideration
for the Acquisition will consist of $1,500,000 in cash, subject to certain adjustments, 240,000 of the Company&rsquo;s common shares
and an unsecured promissory note in the initial principal amount of $800,000 made by Purchaser. The Company intends to fund the
cash portion of the Acquisition purchase price with cash on hand and net proceeds from the contemplated refinancing of its credit
arrangements with First Internet Bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
contains customary representations, warranties, covenants (including non-competition requirements applicable to the selling parties
for a 5 year period) and indemnification provisions. The representations and warranties contained in the Purchase Agreement were
made solely for purposes of the Purchase Agreement, were made solely for the benefit of the parties to the Purchase Agreement and
may not have been intended to be statements of fact but, rather, as a method of allocating risk and governing the contractual rights
and relationships among the parties to the Purchase Agreement. The assertions embodied in those representations and warranties
may be subject to important qualifications and limitations agreed to by the parties in connection with negotiating their terms
and may be subject to a contractual standard of materiality that may be different from what may be viewed as material to shareholders.
For the foregoing reasons, the representations and warranties contained in the Purchase Agreement should not be relied upon as
factual information at the time they were made or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other ancillary
agreements, the Purchase Agreement, contemplates that the Purchaser will enter into lease arrangements for certain premises in
Fort Collins and Livermore, Colorado (the &ldquo;<U>Lease Arrangements</U>&rdquo;) owned indirectly by Seller&rsquo;s shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party&rsquo;s
obligation to consummate the Acquisition is subject to customary conditions as set out in the Purchase Agreement, including, among
others, (i) subject to certain exceptions, the accuracy of the representations and warranties of the parties; (ii) performance
in all material respects by each of the parties of its obligations and satisfaction of its conditions; (iii) the entry into relevant
ancillary documents, including the Lease Arrangements, and (iv) the absence of any change, event, state of facts, development,
occurrence or effect that has or would reasonably be expected to have a material adverse effect, as defined in the Purchase Agreement.
In addition, the Purchase Agreement contains certain customary termination rights of the parties. The Acquisition is expected to
close in the Company&rsquo;s first quarter of fiscal 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Purchase Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Purchase
Agreement, a copy of which will be filed as exhibits to the Company&rsquo;s Quarterly Report on Form 10-Q for the quarterly period
ending December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2019,
the Company issued a press release relating to the Acquisition, a copy of which is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tm1922389d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD><TD STYLE="text-align: justify"><A HREF="tm1922389d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
                                         Release dated November 8, 2019</FONT></A></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document may contain &ldquo;forward-looking
statements&rdquo; within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected
future business and financial performance and financial condition, and often contain words such as &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;seek,&rdquo; &ldquo;see,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
 &ldquo;target,&rdquo; similar expressions, and variations or negatives of these words. Forward-looking statements by their nature
address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed Acquisition
and the anticipated benefits thereof. Such statements involve risks, uncertainties and assumptions. If such risks or uncertainties
materialize or such assumptions prove incorrect, the results of the Company and its subsidiaries could differ materially from those
expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements, including any statements regarding the expected benefits and costs
of the Acquisition contemplated by the Purchase Agreement; the expected timing of the completion of the Acquisition; the ability
of the parties to complete the Acquisition; any statements of expectation or belief; and any statements of assumptions underlying
any of the foregoing. Risks, uncertainties and assumptions include the possibility that expected benefits may not materialize as
expected; that the Acquisition may not be timely completed, if at all; that, prior to the completion of the Acquisition, the Seller&rsquo;s
business may not perform as expected due to transaction-related uncertainty or other factors; that the parties are unable to successfully
implement integration strategies; and other risks that are described in the Company&rsquo;s latest Annual Report on Form 10-K and
its other filings with the SEC. The parties assume no obligation and do not intend to update these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">BIOANALYTICAL SYSTEMS, INC. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: November 8, 2019</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert Leasure, Jr.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Leasure, Jr.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.45in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm1922389d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="logo.jpg" ALT=""></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">NEWS RELEASE</P>



</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>FOR MORE INFORMATION:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Jill C. Blumhoff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: 765.497.8381</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">jblumhoff@BASinc.com</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BASi Announces Expansion into Surgical
Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WEST LAFAYETTE, Ind., November 8, 2019 --&nbsp;Bioanalytical
Systems, Inc.&nbsp;(NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;), a leading provider of nonclinical and analytical
contract research services, today announced that the Company has entered into an agreement to purchase substantially all of the
assets of Pre-Clinical Research Services, Inc. (&ldquo;PCRS&rdquo;), a premier provider of surgical and medical device contract
research services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We have great respect for the people and services provided
by PCRS, and believe the current facilities in Ft. Collins, Colorado, will be an excellent location for future growth,&rdquo; said
Bob Leasure, BASi&rsquo;s President and Chief Executive Officer. &ldquo;Our Companies have worked together for several years on
multiple projects. Becoming one with PCRS will allow us to provide broader services in more areas of research and development than
ever before. The combination will further expand our toxicology business and brings the ability to provide surgical services for
pharmaceutical and medical device clients. We believe this addition is perfectly aligned with our strategy of being right-sized;
small enough to be flexible and responsive, and comprehensive enough to have meaningful impact on our clients&rsquo; product development
needs. The facilities and leadership team at PCRS are an excellent complement to our already strong team, and we look forward to
working with them to continue to build this team and expand the business in the future.&rdquo;<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Donald Maul, founder and president of PCRS, added, &ldquo;At
PCRS we have catered to clients that were focused on medical devices and surgical models&mdash;it has become our brand. Very often
we needed to rely on outside collaborators to fully support a project. By coming together with BASi, we will become much more comprehensive
and have the ability to provide bioanalytical, histology, pathology, and pharmacokinetic evaluations. The combination will also
afford our clients the ability to work in non-human primate models. Formalizing our partnership with BASi makes it easier for our
clients to do more sophisticated projects with a provider that is dedicated to providing quality service.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="footer.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By combining BASi and PCRS, our clients will have the ability
to work with one provider having expertise in a broad range of scientific disciplines, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pharmacology</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Toxicology</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Drug Metabolism</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pharmacokinetics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Bioanalysis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Intravascular Device and Structural Heart Models</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Surgical and Medical Devices</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Scientific and Regulatory Consulting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">The transaction is subject to customary closing processes and is anticipated to close within calendar
2019. A Current Report on Form 8-K containing further details regarding the contemplated transaction has been filed</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bioanalytical Systems, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies
and medical research organizations. The Company focuses on developing innovative services supporting its clients&rsquo; discovery
and development objectives for improved decision-making and accelerated goal attainment. BASi&rsquo;s products focus on increasing
efficiency, improving data, and reducing the cost of taking new drugs to market. Visit&nbsp;www.BASinc.com&nbsp;for more information
about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This release may contain forward-looking statements that
are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market
and demand for our products and services, the development, marketing and sales of products and services, changes in technology,
industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial
impact thereof and various market and operating risks, including those detailed in the Company's filings with the U.S. Securities
and Exchange Commission.</I></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 *L# 2(  A$! Q$!_\0
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M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/
M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/
M_P ([!_S_:C_ .!34?\ ".P?\_VH_P#@4U;%% &/_P ([!_S_:C_ .!34?\
M".P?\_VH_P#@4U;%% '%>)_%5[9:B]C9;(@@&Z0C<22,\9X%9&FZ]XDO+U8;
M2X:>0\[71=H'J>.!3/&5N\/B*9B"%E574^O'/ZUTO@2S2+2)+O;^\GD(S_LK
MP!^>:]EJE2PRFHIMV^\^3@\3B<PE2=1I)O9[)=OP-2[UNUT;2XI_$%U:VCO\
MI 8E6/HHQDUX#XDETVR\6R7?ARZ5K0LL\+1 CRGZE1D<8(R/J*T/B;?S7WCJ
M]CE8^7:A88E/11M!/YDG]*Y <FN2E3M[W<^AG+[/;[SZET;4!JNBV5^!C[1
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M6E#$Y(9"HQQZT<VUQ\N]C"OO%^G:IK6A6VD:FSLUZ/.1%=-R;6X.0,C..*Z
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M HHHH **** "BBB@ HHHH **** "N.U3_D?+?_KE%_Z&:** .QHHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ P\# 2(  A$! Q$!_\0
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M[ABO);"*%-0F:ZCAD>5E&_RHNK[2><8KICX$L_\ A H_"0O+@6JXWS +O?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6-S<*-YE8#!*$DKGC ; ZU>UF5M+O?&-QI=U*MX4LCN^T,2L#;0\@'/1<_,
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MZ\BM+S4+:"XEQLCDD )R<#Z9/ SU->7VWD:1X2\4:5K6%U2>PMTBAD_UD_\
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M502>3@ #)]*Z&LVK.Q:=U<****0PHHHH *" 001D'M17+^.+NXM]/T^&VEN
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M<2F1H QRL>X\_*,#ZYI2A9;C4KF[1114%!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9^HW/\
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MYJ1JP;8K#H"0,]SW-5_^$\TW_GVNO^^5_P :/^$\TW_GVNO^^5_QH_M/#?\
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MO\H>VI]SU6BO*O\ A??AO_H':K_W[C_^+KT+1=<M]<\/6VM6\<J6]Q$9520
M,!SUP2.WK4RI3C\2&JD9;,TZ*XS_ (65I/\ SZWO_?*__%4?\+*TG_GUO?\
MOE?_ (JMOJ6(_D9Q_P!J8/\ Y^+^OD=G17&?\+*TG_GUO?\ OE?_ (JC_A96
MD_\ /K>_]\K_ /%4?4L1_(P_M3!_\_%_7R.SHKC/^%E:3_SZWO\ WRO_ ,51
M_P +*TG_ )];W_OE?_BJ/J6(_D8?VI@_^?B_KY'9T5QG_"RM)_Y];W_OE?\
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MHK\T/TX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ] ?\ Y);=_P#8+F_] :OD]?NCZ5]8/_R2
MV[_[!<W_ * U?)Z_='TK]+RG_=UZ+\C\ZS/^/+U?YL6BBBO3/."BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^J/AY_R2K2/^O(_P!:^5Z^J/AY_P DJTC_ *\C_6N7%_"O4Z,/]KT/
M+1T%+2#H*6O>/@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#8HHHK\-/Z-"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /0'_P"26W?_ &"YO_0&KY/7[H^E?6#_ /)+;O\ [!<W_H#5\GK]T?2O
MTO*?]W7HOR/SK,_X\O5_FQ:***],\X**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZH^'G_ "2K2/\
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MWLP_^$0T3_GS/_?UO\:/^$0T3_GS/_?UO\:W**/J>'_D7W(/K>(_G?WLP_\
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M  *E_P#BJ/\ A3W@?_H$-_X%2_\ Q5=U11[6I_,P]G#L<+_PI[P/_P! AO\
MP*E_^*H_X4]X'_Z!#?\ @5+_ /%5W5%'M:G\S#V<.QPO_"GO _\ T"&_\"I?
M_BJ/^%/>!_\ H$-_X%2__%5W5%'M:G\S#V<.QPO_  I[P/\ ] AO_ J7_P"*
MH_X4]X'_ .@0W_@5+_\ %5W5%'M:G\S#V<.QPO\ PI[P/_T"&_\  J7_ .*H
M_P"%/>!_^@0W_@5+_P#%5W5%'M:G\S#V<.QPO_"GO __ $"&_P# J7_XJC_A
M3W@?_H$-_P"!4O\ \57=44>UJ?S,/9P['"_\*>\#_P#0(;_P*E_^*H_X4]X'
M_P"@0W_@5+_\57=44>UJ?S,/9P['"_\ "GO _P#T"&_\"I?_ (JJU[\+OA]I
MZP&YTMT$\R01_P"D3'+L<*.&KT.N?\5PRS1:0(HGDV:K;.VQ2=JAN2<= /6G
M&K-NW,Q.$4MC$_X5#X%W[/[*.[&<?:I<X_[ZH_X5#X%W[/[).[&<?:I<X_[Z
MJA8: +73=(U&.PF74VUYVEFV-YHB::0$$]0FS''3O3=,T VFD:!?P6$L>JMJ
MTAFG,;>8$9I1ACUV8V\'CI6G-+^=D6C_ "FC_P *B\"EBO\ 91W+R1]KER/_
M !ZE_P"%/^!_^@0W_@5+_P#%5AZ9I\$]MX?M(=.NE\0I< :O+)"ZLT9#"?S)
M",,K9^7D]5QTXGBM]6&G7<5S8WMR?#NGSVD"KNC:[=LJKHPY)$2KR.<N<<T-
MS_F86C_*7;KX7?#RRM'NKG3Q' A"M(;N7 )( 'WO4@4^+X3^!)I9HUT>4-"P
M5MT\P!. >"6Y&".17,/IJ3Z=KL<%DL]B+*R=5MM.DBB:1)6WE5;)9@F,GJ17
M1W%E<1OJVJ65M<8T[4K:\M8TC8>;"+>-9$0=\H7&!W [TVYK[3"T?Y2PWPA\
M"H,MI14#N;J4?^S5UVFZ39:3I$.EV41CLX4\M(]Q.%],GGO7FEU878O[+4M6
MA5;*_2XNI$N[*2YCCF=E\M6C4@AA" H)Z$,.IKO?"%O/:^$].AN6N#(L?'VA
M-D@7)V@C)QA<#DD\<UG4YK:RN5"U[)6,O3/#/A75K>6:VL9-D4\ENV^1Q\T;
M%&[],@U5U'2?!NFWALY+*YFN5C\UXK59IFC3^\P7.!P<9ZXXK4\%*\6GZE#+
M')'(FJW9*NA7AIF92,CD$$'(]:I07T?AKQ3K[ZG#<"/4)([BVN8X'E$BB-4,
M?R@X8%3@'J&X[UI[>KS-<S^\Y_J6&LG[./W(JQ:?X(N)-MM;RSJ;(7RO"TCA
MHBQ7C!R3D'C&:V/^$(\-[@OV/#$9 ,SY/ZUR&JPW4W]I21Z)<:>UWX<E$5M'
M$3M?SG8KE1@.0P8CKECUJ*^L;R77=22XW+J<FI1O92)I\DDPA!388Y=P14 W
M;@?]K.2>;]I5?VW]Y/U3#?\ /J/W([0^"/#@8*;/YCT'GOD_K4-KX2\*WHE-
MM;B40RM#)MF?Y77J#SU%<_)H %CJFIBPE.J#Q")(9MC>8L?VA!\AZA-N[.."
M":W_  59V]C+K\,5G]FE_M.5F'DE-R$Y0@XPPP3TJ76JI7YW]Y2P>&;M[*/W
M(R["Q\%ZG-%'::=?R+*Q5)?L]P(S@D'YR-N.#SFMM?!'AMB0MGDJ<'$[\'\Z
MP-'T;7XOA_*;/4[V*[-K<""R>*- CDOMP=H8'.",GTK*NK7SK:#_ (0NPN[2
M]BTNX2\/D/"V3'\B.6 W2[^0>2,$YYJO:U6])O[R?JF&2UI1^Y':#P1X<;.V
MSS@X.)WX/YTI\#^'0"39$ <G,S_XUR=Y!I,FD7,OAW2=1C:&WMFN/+MWC1@D
MZ.5*G!>4*K$D G&03R*?K,\>N7NMW,<>H+IYBL$6X%D[HQ661F)C."\8R X'
M.*7M*W\[_KYC^J87_GW'[E_D=0?!/AL)O-IA/[QG?'\Z&\$>'$ +6>T$X&9G
M'/YUP<<4[MI\EU806VC1M=* ]E-/:O,60K(L.0R*R[]H.0#NQU%7M.LXK6?3
MAXFM;RZTW^S2EF+BT=Q'(96)5D&XJ^PQA<\X7&<Y%#J5E]M_>+ZIAO\ GU'[
MD=)IGA?PMJU@E[;6,GE.S*-\C@Y5BIXSZ@TZU\*>%;V6ZB@M69[67R9AYD@V
MOM#8Z\\,/SJ?P!!):^"-.AE@F@9?,_=3@AU'F,0&SSG&*F\.PRQ:EXC:2)T6
M34MR%E(#+Y,0R/49!'X5#KU4W[[T\RE@L-I^[C]R,/4=-\&:7?M93V-X\Z1"
M9U@BGEV(20"2F<?=/Y5HVOA/PG?6D%W;0K+!<*'BD6=\.",C'-5]1TS5[OQ?
MJTFG:C/IQ.F0*DJVZNKONFXRP/(R.GK7$?V?)]DV7=DT$4FDV\>GPOI\MQ)&
M^P^8L1##9+YG.6P3\IS@5HJM1KXW]Y+PF&3_ (4?N1Z*?!'AP,%-G@MT!F?G
M]:7_ (0;P[_SXG_O\_\ C7$ZQ':1V/BE/$-M<7>J"W'V*?R6<A!;KC8RY$9#
M[V;D=<G(J6^O)+70/$NGM;7TEW?V\#VB10._FJ;:)"5(&."K9^GO2]I6_G?W
MA]5PO_/J/W(Z2V\-^%+K4=0L8[*02V!03%I'"C>NX8.>>*FE\)^%(;BV@D@5
M9;DD0J9W_>8&XXY].:YG7D>+7M9CGLI'M[B]L7:66"5X4C6$C>RI_K%#J%VY
MQD@G@5#HFGI]KT.>]L)&@AUF\6%VLW18T8$Q$(02B%L$9X'%/VE6U^=_>'U3
M#;>RC]R.R_X0CPV7*?8_F R5\]\X_.E_X0?P[G'V(Y]/.?\ QKCM.M (-(@%
MC=+XNCU-7O;@PN&*^83*S28PT;1Y &<<J ..)8+%?#?A>P\4BTECNK&\GEO0
M5/F2P/(Z$$'DX!1@/]GCK2=2M_._O']4PW_/J/W(Z34/"GA73-/N+Z[M62WM
MT,DC"20X4<G@')JIINA^$]4G:*#2[^-E7=FXAGB4CV+8!/M27>DW=M\*=3@D
MCDEU&ZM9KB=44LQFDRS #O@G 'L*JWUQ%>Z)>6W]HZSJUTZI]EB:Q,#1S;AL
M=7$:@8;!))( !I*M5:^-_>#P>&_Y]Q^Y&ZW@CPXH):SP!U)F?C]:#X)\-JH9
MK/ /0F=_\:Y&.VEA.F_\)!:7$T<5_.=;9H6DCFG*#R9, ?-%CA1C"\ \BH;N
MTA6^LI/L<L'AXVT_V6'4;&6Y1)#*<XC4@IE<;-W09 Q3]I6_G?WA]4PW_/J/
MW(W-3TWP;I-U/;W-C/YD$4,K['<C;++Y2X^;^]U]JV/^$(\.!PGV/YB,@>>^
M?YUP=_8W]O8B.X@OYI/['L/FDMV+D1WA=@V-WS*A!(R3]:LRV=W-X@O1<;UU
M.35UEM95T^2280!U*%9=P18PF0P_W@02>6ZE6WQO[Q?5,-_SZC]R.S_X0CPY
MOV?8_FQG'GOG'YT#P1X<+%19Y8=1Y[Y'ZUS-CH M=-T?48;"5-4;7':6;8WF
M"-II1@GJ(]N..F.:CT*WA.GV4<.GWZ>+HX+C[3<^6R8F*-DS.>'5FP5'/8C
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
